Powder: -20°C for 3 years | In solvent: -80°C for 1 year
4E2RCat is an eIF4E-eIF4G interaction inhibitor (IC50: 13.5 μM).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,500 | |||
5 mg | 在庫あり | ¥ 75,000 | |||
10 mg | 在庫あり | ¥ 114,000 | |||
25 mg | 在庫あり | ¥ 182,000 | |||
50 mg | 在庫あり | ¥ 259,500 | |||
100 mg | 在庫あり | ¥ 349,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 75,500 |
ターゲット&IC50 | eIF4E-eIF4G:13.5 μM |
In vitro | 4E2RCat disrupts the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), thereby inhibiting cap-dependent translation. This action significantly reduces replication of human coronavirus 229E (HCoV-229E), decreasing both the proportion of infected cells and the levels of infectious virus both inside and outside cells. The inhibition of cap-dependent translation by 4E2RCat occurs in a dose-dependent manner, specifically targeting cap-dependent FF translation without affecting EMCV IRES-driven Ren translation. Additionally, 4E2RCat curtails coronavirus replication reliant on dose and duration[1]. |
In vivo | 4E2RCat impedes protein synthesis in vivo, and this effect is not due to elevated cell death[1]. |
分子量 | 455.93 |
分子式 | C22H14ClNO4S2 |
CAS No. | 432499-63-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 15.5 mg/mL (34.00 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
4E2RCat 432499-63-3 Apoptosis PERK 4E-2RCat Virus Protease Inhibitor inhibit Autophagy Eukaryotic Initiation Factor (eIF) inhibitor